Literature DB >> 3033826

Human T-lymphotropic virus type 4 and the human immunodeficiency virus in West Africa.

P J Kanki, S M'Boup, D Ricard, F Barin, F Denis, C Boye, L Sangare, K Travers, M Albaum, R Marlink.   

Abstract

A new human T-lymphotropic virus (HTLV-4) was recently described in healthy people from Senegal. This virus has many properties in common with members of the human T-lymphotropic viruses, particularly the human immunodeficiency virus or HIV, the etiologic agent of acquired immune deficiency syndrome (AIDS), but does not appear to be associated with immunodeficiency-related disorders. In the present study, serum samples were obtained from 4248 individuals from six West African countries, including Senegal, Guinea, Guinea Bissau, Mauritania, Burkina Faso, and Ivory Coast. These samples, collected during 1985-1987, were from people categorized as healthy control, sexually active risk, and disease populations. All samples were analyzed for reactivity to HTLV-4 and HIV by radioimmunoprecipitation-sodium dodecyl sulfate-polyacrylamide gel electrophoresis and immunoblotting. Evidence for HTLV-4 infection was found in five of the six countries. The seroprevalence varied markedly from country to country. Healthy sexually active individuals in the risk category had the highest levels of HTLV-4 infection compared to individuals in the healthy control category and the disease category, the latter including AIDS patients. The seroprevalence of HIV infection in most of these countries was quite low, although tightly associated with the rare cases of AIDS. The biology of HTLV-4 infection thus differs from that of HIV in Central Africa or the United States and Europe. The presence of these viruses and their different pathogenicities in several countries of West Africa indicate the necessity for serologic assays that will distinguish between them. Further studies of their origin and distribution as well as of their biology will be important in advancing our understanding of AIDS.

Entities:  

Mesh:

Year:  1987        PMID: 3033826     DOI: 10.1126/science.3033826

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  25 in total

1.  Monoclonal antibodies and chemiluminescence immunoassay for detection of the surface protein of human T-cell lymphotropic virus.

Authors:  L D Papsidero; R P Dittmer; L Vaickus; B J Poiesz
Journal:  J Clin Microbiol       Date:  1992-02       Impact factor: 5.948

2.  HIV-1 and HIV-2 in Spain.

Authors:  R Savall; X Balanzo; J L Fernandez; F Valls; V Soriano
Journal:  Genitourin Med       Date:  1992-04

3.  Envelope cross-reactivity between human immunodeficiency virus types 1 and 2 detected by different serological methods: correlation between cross-neutralization and reactivity against the main neutralizing site.

Authors:  B Böttiger; A Karlsson; P A Andreasson; A Nauclér; C M Costa; E Norrby; G Biberfeld
Journal:  J Virol       Date:  1990-07       Impact factor: 5.103

4.  Genetic variability between isolates of human immunodeficiency virus (HIV) type 2 is comparable to the variability among HIV type 1.

Authors:  J F Zagury; G Franchini; M Reitz; E Collalti; B Starcich; L Hall; K Fargnoli; L Jagodzinski; H G Guo; F Laure
Journal:  Proc Natl Acad Sci U S A       Date:  1988-08       Impact factor: 11.205

5.  Functional analysis of the Tat trans activator of human immunodeficiency virus type 2.

Authors:  R Fenrick; M H Malim; J Hauber; S Y Le; J Maizel; B R Cullen
Journal:  J Virol       Date:  1989-12       Impact factor: 5.103

6.  Screening of African sera stored for more than 17 years for HIV antibodies by site-directed serology.

Authors:  F Chiodi; G Biberfeld; E Parks; E Norrby; M Mufson
Journal:  Eur J Epidemiol       Date:  1989-03       Impact factor: 8.082

7.  Risk of tuberculosis in patients with HIV-I and HIV-II infections in Abidjan, Ivory Coast.

Authors:  K M De Cock; E Gnaore; G Adjorlolo; M M Braun; M F Lafontaine; G Yesso; G Bretton; I M Coulibaly; G M Gershy-Damet; R Bretton
Journal:  BMJ       Date:  1991-03-02

8.  Computer predictions of functional, topogenic, and antigenic domains in human immunodeficiency virus-2 envelope glycoprotein.

Authors:  Y Becker
Journal:  Virus Genes       Date:  1992-01       Impact factor: 2.332

9.  Computer analysis of the amino acid sequences in gp41 of apathogenic African green monkey (AGM) virus, less pathogenic HIV-2 and highly pathogenic SIV and HIV-1 lentiviruses.

Authors:  Y Becker
Journal:  Virus Genes       Date:  1992-11       Impact factor: 2.332

10.  Potent neutralizing serum immunoglobulin A (IgA) in human immunodeficiency virus type 2-exposed IgG-seronegative individuals.

Authors:  Qin Lizeng; Charlotta Nilsson; Samer Sourial; Sören Andersson; Olav Larsen; Peter Aaby; Mariethe Ehnlund; Ewa Björling
Journal:  J Virol       Date:  2004-07       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.